Introduction {#s0005}
============

Bartter syndrome is an autosomal inherited disorder with clinical characteristics including renal salt wasting, hypokalemic metabolic alkalosis, elevated renin--aldosterone levels with normal or low blood pressure, hypercalciuria and normal serum magnesium levels ([@bb0005]). The last two features distinguish Bartter\'s patients from patients with Gitelman syndrome ([@bb0010]), who, in addition to hypokalemic alkalosis and salt wasting, have hypocalciuria and hypomagnesemia ([@bb0015]). Furthermore, a diuretic test with oral hydrochlorothiazide allows Gitelman syndrome to be differentiated from Bartter syndrome in clinical practice ([@bb0020], [@bb0025]).

These syndromes are caused by mutations in genes encoding channels and transporters involved in electrolyte transport along the nephron. Using linkage analyses of family members, highly significant associations were established between the genes encoding the thick ascending limb (TAL) transporter, *SLC12A1* ([@bb0030]), *KCNJ1* ([@bb0035]) and *CLCNKB* ([@bb0040]) in Bartter syndrome, which were named as Bartter syndrome type I, type II and type III, respectively. The distal convoluted tubule (DCT) Na-Cl co-transporter gene, *SLC12A3* ([@bb0045]) is significantly associated with Gitelman syndrome.

It is evident that the clinical phenotype in patients with *CLCNKB* mutations can be highly variable, from antenatal onset of Bartter syndrome to a phenotype closely resembling Gitelman syndrome ([@bb0050], [@bb0055], [@bb0060]). Clinical overlap of symptoms between Bartter syndrome and Gitelman syndrome is occasionally observed, such that a diuretic test using furosemide and thiazide is still sometimes used to obtain a differential diagnosis between the two syndromes ([@bb0020], [@bb0025]).

Here, we identified a novel missense mutation in *CLCNKB* in a Japanese patient, who presented a Gitelman\'s phenotype with hypocalciuria and hypomagnesemia accompanied by chondrocalcinosis, and was insensitive to thiazide administration.

Patient and methods {#s0020}
===================

Patient {#s0025}
-------

A 45-year-old woman was admitted to our hospital in November 2005 for general fatigue, muscle weakness and hypokalemia. She denied vomiting or diarrhea. She was born at term without hydramnios. Her birth weight was 3030 g. She had felt pain on her knee joint at age 36 and underwent operation of the right knee joint at age 37. She felt numbness on right face and right arm, general fatigue and muscle weakness from age 45. She has experienced no carpopedal spasms. Although hypokalemia was noted before an operation on her right knee joint at age 37, no further studies were conducted at that time. She had not taken magnesium and sodium supplementation or high sodium diet. The patient was a smoker (10 cigarettes/day). Her height and body weight were 161 cm and 39 kg, respectively. Her blood pressure was 102/85 mm Hg, and her grip in both hands was weak. Laboratory findings revealed slightly low serum sodium and chloride levels, but extremely low serum potassium (2.3 mmol/L) and low serum magnesium (1.5 mg/dL) ([Table 1](#t0005){ref-type="table"}). Urine osmolality determined in 24-hour urine ranged from 253 to 421 mOsm/L. Although urinary sodium, chloride and potassium excretion were almost in the normal range, urinary calcium excretion was low (Ca/Cr 0.025 g/gCr). She showed obvious metabolic alkalosis; pH 7.51, bicarbonate 45.3 mmol/L, base excess 18.5 mmol/L. Renin activity (PRA) and aldosterone in her plasma were more than 20 ng/mL/h and 310 pg/mL, respectively.

Conventional radiography {#s0030}
------------------------

Conventional radiography of the antero-posterior view of pelvis showed calcifications in symphysis pubis in the patient ([Fig. 1](#f0005){ref-type="fig"}).

Diuretic tests {#s0035}
--------------

The patient underwent diuretic tests according to a protocol described by [@bb0020] and [@bb0025]. She drank water at 30 mL/kg, followed by intra-venous infusion of a 5% of glucose solution at a rate of 200 mL/h to generate sufficient urinary flow. When urinary flow reached 10 mL/min, samples of urine and serum were obtained to calculate the maximal free water clearance. Subsequently, 20 mg of furosemide (intravenously) or 100 mg of hydrochlorothiazide (orally) was administrated. Samples were collected when urinary flow reached the maximum. Osmolar clearance, maximal free water clearance, chloride clearance and distal fractional chloride reabsorption were calculated. The results were compared to control data from previously published reports ([@bb0065], [@bb0070]).

Gene analysis {#s0040}
-------------

Total DNA was extracted and purified from peripheral leukocytes in a whole-blood sample using a SepaGene DNA extraction kit (WAKO, Japan) ([@bb0075]). All the exons in the coding regions and the flanking intron--exon boundaries of *CLCNKB* and *SLC12A3*, and 2 kb from the 5′ promoter region of *SLC12A3*, were amplified using the specific PCR primers respectively \[[Supplementary Data Table 1](#ec0005){ref-type="supplementary-material"}, [Supplementary Data Table 2](#ec0010){ref-type="supplementary-material"}, [Supplementary Data Table 3](#ec0015){ref-type="supplementary-material"}\]. The DNA was amplified by PfuUltra II Fusion HS DNA polymerase (Agilent Technologies, CA) or TaKaRa LA Taq DNA Polymerase (TaKaRa BIO, Japan) setting the annealing temperatures to those in Supplementary Tables. The PCR-amplified products were then purified using QIA quick PCR amplification kit (QIAGEN, Germany). The sequencing reactions were carried out using the BigDye terminator cycle sequencing kit (Applied Biosystems, CA) and reaction products were analyzed on an ABI-Prism 3100 genetic analyzer (Applied Biosystems, CA) ([@bb0075]).

### MLPA analysis {#s0045}

We used the SALSA MLPA kit P136 SLC12A3 and P266 CLCNKB (MRC Holland, the Netherlands) for the search of genomic rearrangements. The procedure was carried out according to the manufacturer\'s instructions. Ligation products were separated on an ABI PRISM 310 Genetic analyzer (Applied Biosystems, CA). The analysis was performed using GeneMapper v 4.0 (Applied Biosystems, CA).

### Mutation analysis {#s0050}

The functional consequence of the mutation was predicted with web server, Sorting Intolerant From Tolerant (SIFT; <http://sift.jcvi.org/>) ([@bb0080]) and Polymorphism Phenotyping (PolyPhen2; <http://genetics.bwh.harvard.edu/pph2/>) ([@bb0085]).

Results {#s0010}
=======

Diuretic tests {#s0055}
--------------

As shown in [Table 2](#t0010){ref-type="table"}, the maximal free water clearance per 100 mL glomerular filtration rate (CH~2~O) and chloride clearance per 100 mL glomerular filtration rate (CCl) were moderately reduced. The distal fractional chloride reabsorption \[CH~2~O / (CH~2~O + CCl)\] was in normal range. Moreover, the patient responded well to furosemide, inducing an approximately 160-fold increase in chloride clearance (CCl). By contrast, hydrochlorothiazide did not significantly induce chloride excretion. Distal fractional chloride reabsorption \[CH~2~O / (CH~2~O + CCl)\] was apparently decreased by acute furosemide administration, whereas thiazide ingestion had little effect on this parameter.

Gene analysis {#s0060}
-------------

A homozygous mutation in *CLCNKB* was identified in the patient ([Fig. 2](#f0010){ref-type="fig"}), where a cytosine was substituted by thymine (c.1939 C \> T) in exon 19 of *CLCNKB*, such that the amino acid of codon 647 was changed from leucine to phenylalanine (p.Leu647Phe). No mutation was detected in the 5′ upstream region or the coding region of *SLC12A3*, mutations in which are responsible for Gitelman syndrome.

From the results of MLPA analysis, no genomic rearrangement was identified in the region of *SLC12A3* or *CLCNKB*.

### Mutation analysis {#s0065}

The SIFT algorithm predicted p.Leu647Phe was deleterious to effect protein function with a score of 0.01. The PolyPhen-2 also predicted that this mutation was probably damaging with a score of 0.999.

Clinical course {#s0070}
---------------

The patient was treated with potassium chloride (56 mEq/day) and spironolactone (50 mg/day). Her plasma potassium increased from 2.2 mEq/L to 3.0 mEq/L within a month, following a disappearance of symptoms.

Discussion {#s0015}
==========

The clinical symptoms, laboratory data and the results of the diuretic test of this patient all suggested that she was suffering from Gitelman syndrome. Especially, she had felt joint pain in knee and shoulder from age 30\'s. Conventional radiograph revealed calcification in symphysis pubis although no abnormal findings existed in knee or shoulder joint. It might be caused by calcium pyrophosphate deposition suggesting chondrocalcinosis, which was seen in the patients showing hypomagnesemia and hypocalciuria, who were diagnosed as Gitelman syndrome or Bartter syndrome ([@bb0090], [@bb0095]). However, there was no pathological gene mutation and deletion in the coding region or 5′ promoter region of *SLC12A3* in her genome. Further genetic analysis revealed a missense mutation at codon 647 in exon 19 of *CLCNKB*, which caused leucine to be substituted by phenylalanine. The patient was homozygous for this mutation, because of normal allele dosage shown by MLPA analysis. Therefore, she was diagnosed as Bartter syndrome type III, on the basis of the mutation in *CLCNKB*.

Bartter syndrome type III ([@bb0040], [@bb0050]), which is classified as classic Bartter syndrome ([@bb0050]), often occurs in infants, showing polydipsia and polyuria, or failure to thrive. Nephrocalcinosis or severe renal failure is rare. Hypocalciuria and hypomagnesemia are often recognized. A differential diagnosis between Gitelman syndrome and Bartter syndrome type III can be difficult using the results of the examinations of blood chemistry and laboratory tests even though the patients have secondary complication, chondrocalcinosis ([@bb0095]). Therefore, genetic analysis is necessary to elucidate the precise etiology of the disease as they may show Gitelman-like symptoms.

The novel mutation in this patient, p.Leu647Phe, is located at one of the cystathionine beta-synthase (CBS pair) domains ([@bb0100]) in the C-terminus of the chloride channel protein ClC-Kb. This leucine is not only highly conserved between ClC-Ka and ClC-Kb ([@bb0105]), but is also conserved among ClC chloride channels of vertebrates except *Danio rerio*, where the amino acid is isoleucine ([Fig. 3](#f0015){ref-type="fig"}). It is suggested that this mutation may have a serious effect on the chloride transport function of ClC-Kb, which was predicted by SIFT and PolyPhen2. This is the first case report of a missense mutation in *CLCNKB* in a patient who showed a normal response to furosemide and little response to thiazide. The distribution of ClC-Kb in the kidney is broad, from the TAL of the loop of Henle to DCT ([@bb0110], [@bb0115]). Defects in ClC-Kb resulting from a *CLCNKB* mutation might cause secondary dysfunction of thiazide-sensitive sodium-chloride cotransporter NCCT and downregulation of the expression of a member of transient receptor-potential ion-channel family, TRPM6, which may result in renal magnesium wasting at DCT and induce hypomagnesemia ([@bb0120]). On the other hand, ClC-Ka, which has about 90% amino acid sequence similarity with ClC-Kb, is distributed also in the TAL with predominant expression in the thin ascending limb of the loop of Henle ([@bb0125], [@bb0130]). The mouse ClC-K1, which is equivalent to human ClC-Ka, might also mediate some of the diuretic effects of furosemide, as indicated in an *in vitro* expression study using Xenopus oocytes ([@bb0125]) and an *in vivo* study in rats ([@bb0135]). In the diuretic test, this patient showed a good response to furosemide, which might represent normal chloride transport by chloride channels in the TAL, including ClC-Ka. It is thus suggested that in the TAL, ClC-Ka might compensate for the dysfunction of the mutant ClC-Kb and the major defects might be discovered in the distal tubules, where such compensation by ClC-Ka did not exist ([@bb0140], [@bb0145]). Therefore, the phenotype of this patient might be quite similar to that of Gitelman syndrome. Nevertheless, there was the phenotype variability from Gitelman syndrome to classic Bartter syndrome in patients with *CLCNKB* mutations ([@bb0055]), even having the same mutation in one family ([@bb0060]). It might be speculated that it depended on individual differences in distribution of ClC-Kb in the distal nephron or a possibility for activating alternative routes of basolateral chloride secretion to compensate the ClC-Kb defect.

Recently, [@bb0150] suggested a new terminology and pharmacological classification of salt-losing tubulopathies with loop or DCT defects. In this classification, Gitelman syndrome is classified as the pure thiazide type (DC1 type), which is caused by inactivating mutations in *SLC12A3*, and Bartter syndrome type III is classified as the mixed thiazide-furosemide type (DC2 type) by *CLCNKB* mutations. This classification defines the affected sites in the distal nephron and the etiological gene mutations, in contrast to classical typing of antenatal, classical Bartter syndrome and Gitelman syndrome. However, the majority of patients with the DC2 type share symptoms with the pure thiazide type of disorder, DC1 type, making it difficult to differentiate two types, except by genetic analysis.

There is a report of nine Japanese patients that showed the same discrepancies between the diuretic tests and genotypes as this patient. All of them were antenatal or classical Bartter syndrome and had homotypes of nonsense mutations (W391X, W610X), a compound heterotype of nonsense mutations (R76X/W610X) or a mixed type of deletion and nonsense mutation (Exons 1--2 deletion/W610X) ([@bb0155]). The authors considered the reasons why those patients showed a poor response to thiazide, although [@bb0025] reported that two patients of type III Bartter syndrome showed a good response to thiazide. They suggested that the truncation mutation in their patients might cause a more severe dysfunction of the channel than missense or in-frame deletion mutations, as seen in Colussi\'s report. Although our patient had a missense mutation, this mutation might severely affect the function of the channel, because of the substitution of the important amino acid in the CBS domain of ClC-Kb C-terminal.

In conclusion, a novel missense mutation, p.Leu647Phe, in the CBS domain of ClC-Kb caused a phenotype that showed a postnatal (adult-onset) manifestation, a preserved renal concentrating capacity, low plasma levels of magnesium, and diuretic insensitivity to thiazide administration and also suffered from chondrocalcinosis secondary due to hypomagnesemia. These symptoms make it quite difficult to differentiate Bartter syndrome type III from Gitelman syndrome, such that genetic analysis is necessary to correctly diagnose the etiology of the salt-losing tubulopathies.

The following are the supplementary data related to this article.Supplementary Data Table 1List of PCR primers used for amplifying exons and flanking intron regions of *CLCNKB*.Supplementary Data Table 2List of PCR primers used for amplifying exons and flanking intron regions of *SLC12A3*.Supplementary Data Table 3List of PCR primers used for amplifying 5′ promoter regions of *SLC12A3*.
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###### 

Laboratory findings of the patient.

                         Result   Normal range   
  ---------------------- -------- -------------- ------------
  Na                     136      138--146       (mEq/L)
  K                      2.3      3.6--4.9       (mEq/L)
  Cl                     88       99--109        (mEq/L)
  Ca                     9.6      8.7--10.3      (mg/dL)
  Mg                     1.5      1.8--2.5       (mg/dL)
  pH                     7.51     7.35--7.45     
  HCO3^−^                45.3     21--28         (mmol/L)
  Creatinine             0.6      0.4--0.7       (mg/dL)
  PRA                    \> 20    0.3--2.9       (ng/mL/h)
  Aldosterone            310      29.9--159      (pg/mL)
  Urine Na               62       70--250        (mEq/day)
  Urine K                24       25--100        (mEq/day)
  Urine Cl               74       70--250        (mEq/day)
  Urine Ca               50       150--290       (mg/day)
  Urine Mg               64       20--130        (mg/day)
  Urine Ca/Cr            0.025    0.05--0.15     (g/g · Cr)
  Creatinine clearance   63       81--137        (mL/min)

###### 

Diuretic tests of fractional chloride reabsorption.

                          CH~2~O[a](#tf0005){ref-type="table-fn"}   CCl[b](#tf0010){ref-type="table-fn"}   CH~2~O/(CH~2~O + CCl)[c](#tf0015){ref-type="table-fn"}
  ----------------------- ----------------------------------------- -------------------------------------- --------------------------------------------------------
  Before tolerance        6.2                                       0.1                                    98.4
  Furosemide (20 mg iv)   12.5                                      16.1                                   43.9
  Thiazide (100 mg po)    3.6                                       0.6                                    85.7

Water clearance per 100 mL glomerular filtration rate.

Chloride clearance per 100 mL glomerular filtration rate.

Distal fractional chloride reabsorption.
